Droplet-based digital PCR and next generation sequencing for monitoring circulating tumor DNA: a cancer diagnostic perspective

References

• Herceg Z, Hainaut P. Genetic and epigenetic alterations as biomarkers for cancer detection, diagnosis and prognosis. Mol Oncol. 2007;1(1):26–41.
   PubMed Web of Science ®Google Scholar
• Kim R, Emi M, Tanabe K. Cancer immunoediting from immune surveillance to immune escape. Immunology. 2007;121(1):1–14.
   PubMed Web of Science ®Google Scholar
• Garnis C, Buys TP, Lam WL. Genetic alteration and gene expression modulation during cancer progression. Mol Cancer. 2004;3:9.
   PubMed Web of Science ®Google Scholar
• Perkins G, Lu H, Garlan F, et al. Droplet-based digital PCR: application in cancer research. Adv Clin Chem. 2017;79:43–91.
   PubMed Web of Science ®Google Scholar
• Kinde I, Wu J, Papadopoulos N, et al. Detection and quantification of rare mutations with massively parallel sequencing. Proc Natl Acad Sci U S A. 2011;108(23):9530–9535.
   PubMed Web of Science ®Google Scholar
• Newman AM, Bratman SV, To J, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. 2014;20(5):548–554.
   PubMed Web of Science ®Google Scholar
• Pecuchet N, Zonta E, Didelot A, et al. Base-position error rate analysis of next-generation sequencing applied to circulating tumor DNA in non-small cell lung cancer: a prospective study. PLoS Med. 2016;13(12):e1002199.
   PubMed Web of Science ®Google Scholar
• Pécuchet N, Rozenholc Y, Zonta E, et al. Analysis of base-position error rate of next-generation sequencing to detect tumor mutations in circulating DNA. Clin Chem. 2016;62(11):1492–1503.
   PubMed Web of Science ®Google Scholar
• Newman AM, Lovejoy AF, Klass DM, et al. Integrated digital error suppression for improved detection of circulating tumor DNA. Nat Biotechnol. 2016;34(5):547–555.
   PubMed Web of Science ®Google Scholar
• Grizzle WE, Bell WC, Sexton KC. Issues in collecting, processing and storing human tissues and associated information to support biomedical research. Cancer Biomark. 2010;9(1–6):531–549.
   PubMed Web of Science ®Google Scholar
• Allott EH, Geradts J, Sun X, et al. Intratumoral heterogeneity as a source of discordance in breast cancer biomarker classification. Breast Cancer Res. 2016;18(1):68.
   PubMed Web of Science ®Google Scholar
• Remon J, Majem M. EGFR mutation heterogeneity and mixed response to EGFR tyrosine kinase inhibitors of non small cell lung cancer: a clue to overcoming resistance. Transl Lung Cancer Res. 2013;2(6):445–448.
   PubMedGoogle Scholar
• Izumchenko E, Chang X, Brait M, et al. Targeted sequencing reveals clonal genetic changes in the progression of early lung neoplasms and paired circulating DNA. Nature Communications. 2015;6:8258.
   PubMed Web of Science ®Google Scholar
• Punt CJ, Koopman M, Vermeulen L. From tumour heterogeneity to advances in precision treatment of colorectal cancer. Nat Rev Clin Oncol. 2017;14(4):235–246.
   PubMed Web of Science ®Google Scholar
• Umetani N, Hiramatsu S, Hoon DS. Higher amount of free circulating DNA in serum than in plasma is not mainly caused by contaminated extraneous DNA during separation. Ann N Y Acad Sci. 2006;1075:299–307.
   PubMed Web of Science ®Google Scholar
• Caplan L. Delay in breast cancer: implications for stage at diagnosis and survival. Front Public Health. 2014;2:87.
   PubMedGoogle Scholar
• Crowley E, Di Nicolantonio F, Loupakis F, et al. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol. 2013;10(8):472–484.
   PubMed Web of Science ®Google Scholar
• Gao Y, Zhang K, Xi H, et al. Diagnostic and prognostic value of circulating tumor DNA in gastric cancer: a meta-analysis. Oncotarget. 2017;8(4):6330–6340.
   PubMed Web of Science ®Google Scholar
• Pietrasz D, Pécuchet N, Garlan F, et al. Plasma circulating tumor DNA in pancreatic cancer patients is a prognostic marker. Clin Cancer Res. 2017;23(1):116–123.
   PubMed Web of Science ®Google Scholar
• Mandel P, Metais P. C R Seances Soc Biol Fil. 1948;142(3–4):241–243.
   PubMedGoogle Scholar
• Leon SA, Shapiro B, Sklaroff DM, et al. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 1977;37(3):646–650.
   PubMed Web of Science ®Google Scholar
• Stroun M, Anker P, Lyautey J, et al. Isolation and characterization of DNA from the plasma of cancer patients. Eur J Cancer Clin Oncol. 1987;23(6):707–712.
   PubMedGoogle Scholar
• Stroun M, Anker P, Maurice P, et al. Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology. 1989;46(5):318–322.
   PubMed Web of Science ®Google Scholar
• Jahr S, Hentze H, Englisch S, et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 2001;61(4):1659–1665.
   PubMed Web of Science ®Google Scholar
• Millholland JM, Li S, Fernandez CA, et al. Detection of low frequency FGFR3 mutations in the urine of bladder cancer patients using next-generation deep sequencing. Res Rep Urol. 2012;4:33–40.
   PubMedGoogle Scholar
• Pan W, Gu W, Nagpal S, et al. Brain tumor mutations detected in cerebral spinal fluid. Clin Chem. 2015;61(3):514–522.
   PubMed Web of Science ®Google Scholar
• Wang, Y, Springer, S, Mulvey, CL, et al. Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas. Sci Transl Med. 2015;7(293):293ra104.
   PubMed Web of Science ®Google Scholar
• Soh J, Toyooka S, Aoe K, et al. Usefulness of EGFR mutation screening in pleural fluid to predict the clinical outcome of gefitinib treated patients with lung cancer. Int J Cancer. 2006;119(10):2353–2358.
   PubMed Web of Science ®Google Scholar
• Diehl F, Schmidt K, Durkee KH, et al. Analysis of mutations in DNA isolated from plasma and stool of colorectal cancer patients. Gastroenterology. 2008;135(2):489–498.
   PubMed Web of Science ®Google Scholar
• Jiang P, Lo YM. The long and short of circulating cell-free DNA and the ins and outs of molecular diagnostics. Trends Genet. 2016;32(6):360–371.
   PubMed Web of Science ®Google Scholar
• Bronkhorst AJ, Wentzel JF, Aucamp J, et al. Characterization of the cell-free DNA released by cultured cancer cells. Biochim Biophys Acta. 2016;1863(1):157–165.
   PubMed Web of Science ®Google Scholar
• Anker P, Stroun M, Maurice PA. Spontaneous release of DNA by human blood lymphocytes as shown in an in vitro system. Cancer Res. 1975;35(9):2375–2382.
   PubMed Web of Science ®Google Scholar
• Diehl F, Schmidt K, Choti MA, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14(9):985–990.
   PubMed Web of Science ®Google Scholar
• Chan KC, Yeung S-W, Lui W-B, et al. Effects of preanalytical factors on the molecular size of cell-free DNA in blood. Clin Chem. 2005;51(4):781–784.
   PubMed Web of Science ®Google Scholar
• Jung M, Klotzek S, Lewandowski M, et al. Changes in concentration of DNA in serum and plasma during storage of blood samples. Clin Chem. 2003;49(6 Pt 1):1028–1029.
   PubMed Web of Science ®Google Scholar
• Lam NYL, Rainer TH, Chiu RWK, et al. EDTA is a better anticoagulant than heparin or citrate for delayed blood processing for plasma DNA analysis. Clin Chem. 2004;50(1):256–257.
   PubMed Web of Science ®Google Scholar
• El Messaoudi S, Rolet F, Mouliere F, et al. Circulating cell free DNA: preanalytical considerations. Clin Chim Acta. 2013;424:222–230.
   PubMed Web of Science ®Google Scholar
• Benesova L, Belsanova B, Suchanek S, et al. Mutation-based detection and monitoring of cell-free tumor DNA in peripheral blood of cancer patients. Anal Biochem. 2013;433(2):227–234.
   PubMed Web of Science ®Google Scholar
• Bronkhorst AJ, Aucamp J, Pretorius PJ. Cell-free DNA: preanalytical variables. Clin Chim Acta. 2015;450:243–253.
   PubMed Web of Science ®Google Scholar
• Streck. Cell-Free DNA BCT: instructions for use. Omaha (NE); 2014.
   Google Scholar
• Medina Diaz I, Nocon A, Mehnert DH, et al. Performance of streck cfDNA blood collection tubes for liquid biopsy testing. PLoS One. 2016;11(11):e0166354.
   PubMed Web of Science ®Google Scholar
• Sorber L, Zwaenepoel K, Deschoolmeester V, et al. A comparison of cell-free DNA isolation kits: isolation and quantification of cell-free DNA in plasma. J Mol Diagn. 2017;19(1):162–168.
   PubMed Web of Science ®Google Scholar
• Kang Q, Henry NL, Paoletti C, et al. Comparative analysis of circulating tumor DNA stability in K3EDTA, streck, and cellsave blood collection tubes. Clin Biochem. 2016;49(18):1354–1360.
   PubMed Web of Science ®Google Scholar
• Henao Diaz E, Yachnin J, Grönberg H, et al. The in vitro stability of circulating tumour DNA. PLoS One. 2016;11(12):e0168153.
   PubMed Web of Science ®Google Scholar
• Underhill HR, Kitzman JO, Hellwig S, et al. Fragment length of circulating tumor DNA. PLoS Genet. 2016;12(7):e1006162.
   PubMed Web of Science ®Google Scholar
• Devonshire AS, Whale AS, Gutteridge A, et al. Towards standardisation of cell-free DNA measurement in plasma: controls for extraction efficiency, fragment size bias and quantification. Anal Bioanal Chem. 2014;406(26):6499–6512.
   PubMed Web of Science ®Google Scholar
• Diehl F, Li M, Dressman D, et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A. 2005;102(45):16368–16373.
   PubMed Web of Science ®Google Scholar
• Thijssen MA, Swinkels DW, Ruers TJM, et al. Difference between free circulating plasma and serum DNA in patients with colorectal liver metastases. Anticancer Res. 2002;22(1A):421–425.
   PubMed Web of Science ®Google Scholar
• Gormally E, Caboux E, Vineis P, et al. Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance. Mutat Res. 2007;635(2–3):105–117.
   PubMed Web of Science ®Google Scholar
• Fleischhacker M, Schmidt B. Circulating nucleic acids (CNAs) and cancer–a survey. Biochim Biophys Acta. 2007;1775(1):181–232.
   PubMed Web of Science ®Google Scholar
• Swarup V, Rajeswari MR. Circulating (cell-free) nucleic acids–a promising, non-invasive tool for early detection of several human diseases. FEBS Lett. 2007;581(5):795–799.
   PubMed Web of Science ®Google Scholar
• Akirav EM, Lebastchi J, Galvan EM, et al. Detection of β cell death in diabetes using differentially methylated circulating DNA.. Proc Natl Acad Sci U S A. 2011;108(47):19018–19023.
   PubMed Web of Science ®Google Scholar
• Lehmann-Werman R, Neiman D, Zemmour H, et al. Identification of tissue-specific cell death using methylation patterns of circulating DNA. Proc Natl Acad Sci U S A. 2016;113(13):E1826–34.
   PubMed Web of Science ®Google Scholar
• Garlan F, Laurent-Puig P, Sefrioui D, et al. Early evaluation of circulating tumor DNA as marker of therapeutic efficacy in metastatic colorectal cancer patients (PLACOL study). Clin Cancer Res. 2017;23:5416–5425.
   PubMed Web of Science ®Google Scholar
• Hamakawa T, Kukita Y, Kurokawa Y, et al. Monitoring gastric cancer progression with circulating tumour DNA. Br J Cancer. 2015;112(2):352–356.
   PubMed Web of Science ®Google Scholar
• Chae YK, Davis AA, Jain S, et al. Concordance of genomic alterations by next-generation sequencing in tumor tissue versus circulating tumor DNA in breast cancer. Mol Cancer Ther. 2017;16:1412–1420.
   PubMed Web of Science ®Google Scholar
• Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6(224):224ra24.
   PubMed Web of Science ®Google Scholar
• Garrigou S, Perkins G, Garlan F, et al. A study of hypermethylated circulating tumor DNA as a universal colorectal cancer biomarker. Clin Chem. 2016;62(8):1129–1139.
   PubMed Web of Science ®Google Scholar
• Butt AN, Swaminathan R. Overview of circulating nucleic acids in plasma/serum. Ann N Y Acad Sci. 2008;1137:236–242.
   PubMed Web of Science ®Google Scholar
• Scholer LV, Reinert T, Ørntoft M-BW, et al. Clinical implications of monitoring circulating tumor DNA in patients with colorectal cancer. Clin Cancer Res. 2017.
   PubMed Web of Science ®Google Scholar
• Zhou J, Chang L, Guan Y, et al. Application of circulating tumor DNA as a non-invasive tool for monitoring the progression of colorectal cancer. PLoS One. 2016;11(7):e0159708.
   PubMed Web of Science ®Google Scholar
• Pantel K. Blood-based analysis of circulating cell-free DNA and tumor cells for early cancer detection. PLoS Med. 2016;13(12):e1002205.
   PubMed Web of Science ®Google Scholar
• Liu Y, Hernandez AM, Shibata D, et al. BCL2 translocation frequency rises with age in humans. Proc Natl Acad Sci U S A. 1994;91(19):8910–8914.
   PubMed Web of Science ®Google Scholar
• Shriner D, Rodrigo AG, Nickle DC, et al. Pervasive genomic recombination of HIV-1 in vivo. Genetics. 2004;167(4):1573–1583.
   PubMed Web of Science ®Google Scholar
• Vogelstein B, Kinzler KW. Digital PCR. Proc Natl Acad Sci U S A. 1999;96(16):9236–9241.
   PubMed Web of Science ®Google Scholar
• Zhang C, Xing D. Single-molecule DNA amplification and analysis using microfluidics. Chem Rev. 2010;110(8):4910–4947.
   PubMed Web of Science ®Google Scholar
• Morrison T, Hurley J, Garcia J, et al. Nanoliter high throughput quantitative PCR. Nucleic Acids Res. 2006;34(18):e123.
   PubMed Web of Science ®Google Scholar
• Shen F, Du W, Davydova EK, et al. Nanoliter multiplex PCR arrays on a SlipChip. Anal Chem. 2010;82(11):4606–4612.
   PubMed Web of Science ®Google Scholar
• Leamon JH, Lee WL, Tartaro KR, et al. A massively parallel PicoTiterPlate based platform for discrete picoliter-scale polymerase chain reactions. Electrophoresis. 2003;24(21):3769–3777.
   PubMed Web of Science ®Google Scholar
• Kelly BT, Baret J-C, Taly V, et al. Miniaturizing chemistry and biology in microdroplets. Chem Commun (Camb). 2007;18:1773–1788.
   PubMed Web of Science ®Google Scholar
• Chetverina HV, Chetverin AB. Cloning of RNA molecules in vitro. Nucleic Acids Res. 1993;21(10):2349–2353.
   PubMed Web of Science ®Google Scholar
• Perez-Toralla K, Pekin D, Bartolo J-F, et al. [Digital PCR compartmentalization I. Single-molecule detection of rare mutations]. Med Sci (Paris). 2015;31(1):84–92.
   PubMed Web of Science ®Google Scholar
• Taly V, Pekin D, El Abed A, et al. Detecting biomarkers with microdroplet technology. Trends Mol Med. 2012;18(7):405–416.
   PubMed Web of Science ®Google Scholar
• Caen O, Nizard P, Garrigou S, et al. [Digital PCR compartmentalization II. Contribution for the quantitative detection of circulating tumor DNA]. Med Sci (Paris). 2015;31(2):180–186.
   PubMed Web of Science ®Google Scholar
• Williams R, Peisajovich SG, Miller OJ, et al. Amplification of complex gene libraries by emulsion PCR. Nat Methods. 2006;3(7):545–550.
   PubMed Web of Science ®Google Scholar
• Dressman D, Yan H, Traverso G, et al. Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proc Natl Acad Sci U S A. 2003;100(15):8817–8822.
   PubMed Web of Science ®Google Scholar
• Li M, Diehl F, Dressman D, et al. BEAMing up for detection and quantification of rare sequence variants. Nat Methods. 2006;3(2):95–97.
   PubMed Web of Science ®Google Scholar
• Taly V, Pekin D, Benhaim L, et al. Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients. Clin Chem. 2013;59(12):1722–1731.
   PubMed Web of Science ®Google Scholar
• Zhong Q, Bhattacharya S, Kotsopoulos S, et al. Multiplex digital PCR: breaking the one target per color barrier of quantitative PCR. Lab Chip. 2011;11(13):2167–2174.
   PubMed Web of Science ®Google Scholar
• McDermott GP, Do D, Litterst CM, et al. Multiplexed target detection using DNA-binding dye chemistry in droplet digital PCR. Anal Chem. 2013;85(23):11619–11627.
   PubMed Web of Science ®Google Scholar
• Madic J, Zocevic A, Senlis V, et al. Three-color crystal digital PCR. Biomol Detect Quantif. 2016;10:34–46.
   PubMedGoogle Scholar
• Andersen RF, Jakobsen A. Screening for circulating RAS/RAF mutations by multiplex digital PCR. Clin Chim Acta. 2016;458:138–143.
   PubMed Web of Science ®Google Scholar
• Zonta E, Garlan F, Pécuchet N, et al. Multiplex detection of rare mutations by picoliter droplet based digital PCR: sensitivity and specificity considerations. PLoS One. 2016;11(7):e0159094.
   PubMed Web of Science ®Google Scholar
• Siravegna G, Marsoni S, Siena S, et al. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol. 2017;14(9):531–548.
   PubMed Web of Science ®Google Scholar
• Shu Y, Wu X, Tong X, et al. Circulating tumor DNA mutation profiling by targeted next generation sequencing provides guidance for personalized treatments in multiple cancer types. Sci Rep. 2017;7(1):583.
   PubMed Web of Science ®Google Scholar
• Wan JCM, Massie C, Garcia-Corbacho J, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017;17(4):223–238.
   PubMed Web of Science ®Google Scholar
• Wielscher M, Vierlinger K, Kegler U, et al. Diagnostic performance of plasma DNA methylation profiles in lung cancer, pulmonary fibrosis and COPD. EBioMedicine. 2015;2(8):929–936.
   PubMed Web of Science ®Google Scholar
• Koukoura O, Spandidos DA, Daponte A, et al. DNA methylation profiles in ovarian cancer: implication in diagnosis and therapy (Review). Mol Med Rep. 2014;10(1):3–9.
   PubMed Web of Science ®Google Scholar
• Giannopoulou L, Chebouti I, Pavlakis K, et al. RASSF1A promoter methylation in high-grade serous ovarian cancer: A direct comparison study in primary tumors, adjacent morphologically tumor cell-free tissues and paired circulating tumor DNA. Oncotarget. 2017;8(13):21429–21443.
   PubMed Web of Science ®Google Scholar
• Garlan F, Blanchet B, Kramkimel N, et al. Circulating tumor DNA measurement by picoliter droplet-based digital pcr and vemurafenib plasma concentrations in patients with advanced BRAF-mutated melanoma. Target Oncol. 2017;12(3):365–371.
   PubMed Web of Science ®Google Scholar
• P, L.-P.. RAS mutations concordance in circulating tumor DNA (ctDNA) and tissue in metastatic colorectal cancer (mCRC): RASANC, an AGEO prospective multicenter study. J Clin Oncol. 2017;35(suppl):abstr 11509.
   Google Scholar
• Fan G, Zhang K, Yang X, et al. Prognostic value of circulating tumor DNA in patients with colon cancer: systematic review. PLoS One. 2017;12(2):e0171991.
   PubMed Web of Science ®Google Scholar
• Tie, J, Wang, Y, Tomasetti, C, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med. 2016;8(346):346ra92.
   PubMed Web of Science ®Google Scholar
• Schrock A, Leisse A, De Vos L, et al. Free-circulating methylated DNA in blood for diagnosis, staging, prognosis, and monitoring of head and neck squamous cell carcinoma patients: an observational prospective cohort study. Clin Chem. 2017.
   PubMed Web of Science ®Google Scholar
• Qureshi SA, Bashir MU, Yaqinuddin A. Utility of DNA methylation markers for diagnosing cancer. Int J Surg. 2010;8(3):194–198.
   PubMed Web of Science ®Google Scholar
• Wang Y-Q, Yan Q, Zhang J-R, et al. Epigenetic inactivation of BRCA1 through promoter hypermethylation in ovarian cancer progression. J Obstet Gynaecol Res. 2013;39(2):549–554.
   PubMed Web of Science ®Google Scholar
• Ruscito I, Dimitrova D, Vasconcelos I, et al. BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients–a study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD). Eur J Cancer. 2014;50(12):2090–2098.
   PubMed Web of Science ®Google Scholar
• Olmedillas Lopez S, García-Olmo D, García-Arranz M, et al. KRAS G12V mutation detection by droplet digital PCR in circulating cell-free DNA of colorectal cancer patients. Int J Mol Sci. 2016;17(4):484.
   PubMed Web of Science ®Google Scholar
• Bournet B, Dufresne M, Selves J, et al. [Kras oncogene and pancreatic cancer: thirty years after]. Med Sci (Paris). 2013;29(11):991–997.
   PubMed Web of Science ®Google Scholar
• Sanmamed MF, Fernández-Landázuri S, Rodríguez C, et al. Quantitative cell-free circulating BRAFV600E mutation analysis by use of droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors. Clin Chem. 2015;61(1):297–304.
   PubMed Web of Science ®Google Scholar
• Suzawa K, Yamamoto H, Ohashi K, et al. Optimal method for quantitative detection of plasma EGFR T790M mutation using droplet digital PCR system. Oncol Rep. 2017;37(5):3100–3106.
   PubMed Web of Science ®Google Scholar
• Kinugasa H, Nouso K, Tanaka T, et al. Droplet digital PCR measurement of HER2 in patients with gastric cancer. Br J Cancer. 2015;112(10):1652–1655.
   PubMed Web of Science ®Google Scholar
• Takeshita T, Yamamoto Y, Yamamoto-Ibusuki M, et al. Prognostic role of PIK3CA mutations of cell-free DNA in early-stage triple negative breast cancer. Cancer Sci. 2015;106(11):1582–1589.
   PubMed Web of Science ®Google Scholar
• Takai E, Totoki Y, Nakamura H, et al. Clinical utility of circulating tumor DNA for molecular assessment in pancreatic cancer. Sci Rep. 2015;5:18425.
   PubMed Web of Science ®Google Scholar
• Chen KZ, Lou F, Yang F, et al. Circulating tumor DNA detection in early-stage non-small cell lung cancer patients by targeted sequencing. Sci Rep. 2016;6:31985.
   PubMed Web of Science ®Google Scholar
• Beaver JA, Jelovac D, Balukrishna S, et al. Detection of cancer DNA in plasma of patients with early-stage breast cancer. Clin Cancer Res. 2014;20(10):2643–2650.
   PubMed Web of Science ®Google Scholar
• Garcia-Murillas, I, Schiavon, G, Weigelt, B, et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med. 2015;7(302):302ra133.
   PubMed Web of Science ®Google Scholar
• Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):pl1.
   PubMed Web of Science ®Google Scholar
• Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401–404.
   PubMed Web of Science ®Google Scholar
• Song, L, Jia, J, Peng, X, et al. The performance of the SEPT9 gene methylation assay and a comparison with other CRC screening tests: a meta-analysis. Sci Rep. 2017;7(1):3032.
   PubMed Web of Science ®Google Scholar
• Uehiro N, Sato F, Pu F, et al. Circulating cell-free DNA-based epigenetic assay can detect early breast cancer. Breast Cancer Res. 2016;18(1):129.
   PubMed Web of Science ®Google Scholar
• Jiao L, Zhu J, Hassan MM, et al. K-ras mutation and p16 and preproenkephalin promoter hypermethylation in plasma DNA of pancreatic cancer patients: in relation to cigarette smoking. Pancreas. 2007;34(1):55–62.
   PubMed Web of Science ®Google Scholar
• Cancer control: early detection. WHO Guide for effective programmes. Geneva: World Health Organization; 2007 (http://apps.who.int/iris/bitstream/10665/43743/1/9241547338_eng. pdf,
   Google Scholar
• Epigenomics receives FDA approval for Epi proColon [news release]. Berlin (Germany): Epigenomics, Inc.; April 13, 2016. http://www.epigenomics.com/blog/2016/04/13/epigenomics-receives-fda-approval-epi-procolon-2/.
   Google Scholar
• Epi proColon test: Instructions for use (IFU 0008) and Epigenomics data on file, P130001. Epigenomics AG. https://www.accessdata.fda.gov/cdrh_docs/pdf13/P130001C.pdf.
   Google Scholar
• Kisiel JB, Raimondo M, Taylor WR, et al. New DNA methylation markers for pancreatic cancer: discovery, tissue validation, and pilot testing in pancreatic juice. Clin Cancer Res. 2015;21(19):4473–4481.
   PubMed Web of Science ®Google Scholar
• Herreros-Villanueva M, Bujanda L. Non-invasive biomarkers in pancreatic cancer diagnosis: what we need versus what we have. Ann Transl Med. 2016;4(7):134.
   PubMed Web of Science ®Google Scholar
• Fernandez-Cuesta L, Perdomo S, Avogbe PH, et al. Identification of circulating tumor DNA for the early detection of small-cell lung cancer. EBioMedicine. 2016;10:117–123.
   PubMed Web of Science ®Google Scholar
• Le Calvez-Kelm F, Foll M, Wozniak MB, et al. KRAS mutations in blood circulating cell-free DNA: a pancreatic cancer case-control. Oncotarget. 2016;7(48):78827–78840.
   PubMed Web of Science ®Google Scholar
• Chan TL, Zhao W, Leung SY, et al. BRAF and KRAS mutations in colorectal hyperplastic polyps and serrated adenomas. Cancer Res. 2003;63(16):4878–4881.
   PubMed Web of Science ®Google Scholar
• Yamanishi Y, Boyle DL, Rosengren S, et al. Regional analysis of p53 mutations in rheumatoid arthritis synovium. Proc Natl Acad Sci U S A. 2002;99(15):10025–10030.
   PubMed Web of Science ®Google Scholar
• Tschandl P, Berghoff AS, Preusser M, et al. NRAS and BRAF mutations in melanoma-associated nevi and uninvolved nevi. PLoS One. 2013;8(7):e69639.
   PubMed Web of Science ®Google Scholar
• Daniotti M, Vallacchi V, Rivoltini L, et al. Detection of mutated BRAFV600E variant in circulating DNA of stage III-IV melanoma patients. Int J Cancer. 2007;120(11):2439–2444.
   PubMed Web of Science ®Google Scholar
• Ibanez De Caceres I, Battagli C, Esteller M, et al. Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients. Cancer Res. 2004;64(18):6476–6481.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang R, Song H, et al. Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer. Cancer Lett. 2011;303(1):21–28.
   PubMed Web of Science ®Google Scholar
• Radpour R, Barekati Z, Kohler C, et al. Hypermethylation of tumor suppressor genes involved in critical regulatory pathways for developing a blood-based test in breast cancer. PLoS One. 2011;6(1):e16080.
   PubMed Web of Science ®Google Scholar
• Belinsky SA, Klinge DM, Dekker JD, et al. Gene promoter methylation in plasma and sputum increases with lung cancer risk. Clin Cancer Res. 2005;11(18):6505–6511.
   PubMed Web of Science ®Google Scholar
• Hsu H-S, Chen T-P, Hung C-H, et al. Characterization of a multiple epigenetic marker panel for lung cancer detection and risk assessment in plasma. Cancer. 2007;110(9):2019–2026.
   PubMed Web of Science ®Google Scholar
• Chen H, Tu H, Meng ZQ, et al. K-ras mutational status predicts poor prognosis in unresectable pancreatic cancer. Eur J Surg Oncol. 2010;36(7):657–662.
   PubMed Web of Science ®Google Scholar
• Lennon AM, Wolfgang CL, Canto MI, et al. The early detection of pancreatic cancer: what will it take to diagnose and treat curable pancreatic neoplasia? Cancer Res. 2014;74(13):3381–3389.
   PubMed Web of Science ®Google Scholar
• Pekin D, Skhiri Y, Baret J-C, et al. Quantitative and sensitive detection of rare mutations using droplet-based microfluidics. Lab Chip. 2011;11(13):2156–2166.d
   PubMed Web of Science ®Google Scholar